West Pharma price target raised by UBS; rating kept at Buy
UBS maintained West Pharma at Buy and raised its price target to $415.00 per share from $340.00, according to TradingView News and Benzinga’s ratings action summary.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.